Structure of Talazoparib
CAS No.: 1207456-01-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor, with Kis of 1.2 nM and 0.87 nM for PARP1 and PARP2, respectively. It has antitumor activity.
Synonyms: BMN-673; LT-673
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Preclinical evaluation of a novel antibody–drug conjugate OBI-992 for Cancer therapy
Ting-Yu Chang ; Chun-Jung Lin ; Shih-NiWen ; Yi-ChenWu ; Cheng-Yen Wei ; Jye-Yu Huang , et al.
Abstract: Trophoblast cell surface antigen 2 (TROP2), a transmembrane glycoprotein highly expressed in a variety of epithelial cancers, has been considered as a primary therapeutic target for the development of antibody–drug conjugates (ADCs). OBI-992, an investigational TROP2-targeted ADC, is composed of a novel TROP2 antibody (R4702) conjugated to the topoisomerase I (TOP1) inhibitor exatecan through a hydrophilic enzyme-cleavable linker. This study aimed to characterize R4702 and OBI-992 in vitro. TROP2-targeted antibodies sacituzumab and datopotamab were employed as the comparators for R4702. ADCs sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) were used as benchmarks for OBI-992. Results revealed that R4702 binds to an epitope that is distinct from sacituzumab and datopotamab. The cytotoxicity of the OBI-992, SG, and Dato-DXd against different cancer cells is comparable despite they have different internalization profile. Upregulation of breast cancer resistance protein (BCRP) was observed in SG-resistant and Dato-DXd-resistant cells, but not in OBI-992-resistant cells. In addition, significant downregulation of TROP2 expression was detected with Dato-DXd-resistant cells and only slightly downregulation with SG- and OBI-992-resistant cells was observed. Moreover, substantial enhancement of cytotoxicity and DNA damage was found in the combination of OBI-992 with a poly (ADP-ribose) polymerase (PARP) inhibitor (talazoparib). Taken together, the findings in this study support further clinical development of OBI-992.
Show More >
Keywords: TROP2 ; Topoisomerase I inhibitors ; OBI-992 ; Antibody–drug conjugate ; Exatecan
Show More >
CAS No. : | 1207456-01-6 |
Formula : | C19H14F2N6O |
M.W : | 380.35 |
SMILES Code : | O=C1NN=C2C3=C1C=C(F)C=C3N[C@H](C4=CC=C(F)C=C4)[C@H]2C5=NC=NN5C |
Synonyms : |
BMN-673; LT-673
|
MDL No. : | MFCD22666357 |
InChI Key : | HWGQMRYQVZSGDQ-HZPDHXFCSA-N |
Pubchem ID : | 135565082 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
mouse embryonic stem cells | 25 nM | 6 days | To screen for mutants resistant to Talazoparib, identified Parp1 mutations causing resistance | PMC5945626 |
HeLa cells | 1 µM | 12 days | To screen for PARP1 mutants resistant to Talazoparib, identified PARP1 DNA-binding domain mutations causing resistance | PMC5945626 |
HCT116-p53WT | 10-100 nM | 48 h | To evaluate the effect of Talazoparib in combination with TAS102 on DNA damage in p53WT cells, results showed that the combination significantly increased the fluorescence intensity of DNA damage markers gH2AX and RAD51. | PMC10982975 |
HCT116-p53KO | 10-100 nM | 48 h | To evaluate the effect of Talazoparib in combination with TAS102 on DNA damage in p53KO cells, results showed that the combination significantly increased the fluorescence intensity of DNA damage markers gH2AX and RAD51. | PMC10982975 |
MCF-7 | 200 nM | 0-48 h | To evaluate the effect of talazoparib on autophagy initiation factors, results showed significant increase in ATG3, ATG5, ATG7, and ATG16L1 levels | PMC8007595 |
MDA-MB-231 | 200 nM | 24-48 h | To evaluate the effect of talazoparib on autophagy, results showed significant increase in endogenous LC3B punctae | PMC8007595 |
FaDu | 8 nM | To evaluate the effect of Talazoparib on the proliferation of FaDu cells expressing H3K36M | PMC10903949 | |
HSC-2 | 8 nM | To evaluate the effect of Talazoparib on the proliferation of HSC-2 cells expressing H3K36M | PMC10903949 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
BALB/c nude mice | SUM149 cell xenograft model | oral | 0.66 mg/ml | 3 days on, 4 days off | To evaluate the effect of PARP1 mutation on Talazoparib treatment, found that PARP1 mutation caused tumors to be unresponsive to Talazoparib | PMC5945626 |
Mice | HT29 tumor model | Oral | 0.15 mg/kg | Once daily for 5 days, followed by 2 days off | To evaluate the anti-tumor efficacy of Talazoparib in combination with TAS102 in the HT29 tumor model, results showed that the combination significantly inhibited tumor growth and improved survival. | PMC10982975 |
SCID mice | MCF-7 xenograft tumour model | Oral | 2 mg/kg | Every other day for 30 days | To evaluate the effect of talazoparib and chloroquine combination therapy on tumour volume, results showed significant reduction in tumour volume | PMC8007595 |
Mice | PDX models | Oral | 0.33mg/kg | 6 days on/1 day off for 28 days | To evaluate the in vivo response of the PARP inhibitor talazoparib in PDX models representing the CN-high/p53mut and MMRd subtypes. The results showed that two out of four CN-high models exhibited stable disease, while the other two showed significant tumor growth inhibition, and no significant tumor growth inhibition was observed in the MMRd models. | PMC8751371 |
mice | HNSCC xenograft model | intraperitoneal injection | 50 mg/kg | once daily for the duration of the experiment | To evaluate the effect of Talazoparib on tumor burden in H3K36M HNSCC xenograft model | PMC10903949 |
Mice | STAG2-mutant AML model | Oral | 0.25 mg/kg | Once daily for 4 weeks | To evaluate the effect of Talazoparib on STAG2-mutant AML model, results showed that Talazoparib significantly reduced the burden of mutant cells. | PMC7934867 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03148795 | Prostate Cancer | PHASE2 | COMPLETED | 2023-03-31 | Arizona Oncology Associates, T... More >>empe, Arizona, 85284, United States|City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, 91010, United States|City of Hope-Antelope Valley, Lancaster, California, 93534, United States|UC Irvine Health Investigational Drug Pharmacy, Orange, California, 92868, United States|University of California, Irvine Medical Center, Orange, California, 92868, United States|Medical Oncology Associates-SD, San Diego, California, 92123, United States|Sharp Outpatient Infusion Therapy Center, San Diego, California, 92123, United States|Sharp Rees-Stealy, San Diego, California, 92123, United States|Emory University Hospital, Atlanta, Georgia, 30322, United States|The Emory Clinic, Atlanta, Georgia, 30322, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, 30322, United States|Piedmont Cancer Institute, PC, Fayetteville, Georgia, 30214, United States|Piedmont Cancer Institute, PC, Newnan, Georgia, 30265, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, 63141, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, 63129, United States|Christian Hospital North East, Saint Louis, Missouri, 63136, United States|Siteman Cancer Center - St. Peters, Saint Peters, Missouri, 63376, United States|Weill Cornell Medical Center - New York Presbyterian Hospital, New York, New York, 10021, United States|Weill Cornell Medical Center-New York Presbyterian Hospital, New York, New York, 10021, United States|Levine Cancer Institute-Albermarle, Albemarle, North Carolina, 28001, United States|Carolinas Medical Center, Charlotte, North Carolina, 28203, United States|Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|Levine Cancer Institute-Pineville, Charlotte, North Carolina, 28210, United States|Levine Cancer Institute-Southpark, Charlotte, North Carolina, 28211, United States|Levine Cancer Institute-University, Charlotte, North Carolina, 28262, United States|Levine Cancer Institute-Ballantyne, Charlotte, North Carolina, 28277, United States|Levine Cancer Institute- Gaston, Gastonia, North Carolina, 28054, United States|Levine Cancer Institute-Lincolnton, Lincolnton, North Carolina, 28092, United States|Levine Cancer Institute-Monroe, Monroe, North Carolina, 28112, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, 29572, United States|Parkway Surgery Center, Myrtle Beach, South Carolina, 29572, United States|Levine Cancer Institute-Rock Hill, Rock Hill, South Carolina, 29732, United States|The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center, Tyler, Texas, 75701, United States|Virginia Oncology Associates, Hampton, Virginia, 23666, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Swedish Cancer Institute Edmonds Campus, Edmonds, Washington, 98026, United States|Swedish Cancer Institute Issaquah Campus, Issaquah, Washington, 98029, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|Froedtert Hospital/Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Medical Imaging St Vincent's Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|St Vincent's Hospital Sydney, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, 2010, Australia|PRP Diagnostic Imaging, Westmead, New South Wales, 2145, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, 4066, Australia|Liz Plummer Cancer Care Center, Cairns, Queensland, 4870, Australia|Icon Cancer Care Chermside, Chermside, Queensland, 4032, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, 4101, Australia|Icon Cancer Care, South Brisbane, Queensland, 4101, Australia|Intergrated Clinical Oncology Network (ICON), South Brisbane, Queensland, 4101, Australia|Icon Cancer Care Southport, Southport, Queensland, 4215, Australia|Eastern Clinical Research Unit, Box Hill, Victoria, 3128, Australia|Eastern Health Pathology Service, Box Hill, Victoria, 3128, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Peninsula Health, Frankston, Victoria, 3199, Australia|Olivia Newton John Cancer Wellness & Research Centre Austin Health, Heidelberg, Victoria, 3084, Australia|Ordensklinikum Linz, Barmherzige Schwestern, Linz, Upper Austria, 4010, Austria|Vinzenz Pathologieverbund, Linz, Upper Austria, 4010, Austria|Ordensklinikum Linz GmbH, Elisabethinen, Linz, Upper Austria, 4020, Austria|Paracelsus Medical University, SALK, Salzburg, 5020, Austria|Isotopix-Ambulatorium fur Nuklearmedizin, Vienna, 1090, Austria|Medical University of Vienna, Vienna, 1090, Austria|Medizinische Universitat Wien, Vienna, 1090, Austria|Diagnosezentrum Meidling, Vienna, 1120, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, 1200, Belgium|Algemeen Ziekenhuis Sint-Lucas, Gent, 9000, Belgium|UZ Leuven, Campus Gasthuisberg, Leuven, 3000, Belgium|Hospital de Caridade de Ijui, Ijui, RIO Grande DO SUL, 98700-000, Brazil|Hospital de Clinicas de Porto Alegre-HCPA, Porto Alegre, RS, 90035-903, Brazil|Fundacao Pio XII-Hospital de Cancer de Barretos, Barretos, SAO Paulo, 14784-400, Brazil|Fundacao Doutor Amaral Carvalho, Jau, SAO Paulo, 17210-120, Brazil|ICO-Site Paul Papin, Angers Cedex 02, 49055, France|CHRUBesangon-H6pital Jean Minjoz, Besancon, 25030, France|Institut Bergonie, Service d'Oncologie, Bordeaux cedex, 33076, France|Centre Hospitalier Departemental Les Oudairies, La Roche sur Yon, 85925, France|Clinique Victor Hugo-Centre Jean Bernard, Le Mans Cedex 02, 72015, France|Institut de Cancerologie Strasbourg Europe, Strasbourg, 67200, France|Hopital Foch Service Oncologie, Suresnes Cedex, 92151, France|Institut Gustave Roussy, VILLEJUIF cedex, 94805, France|Universitaetsklinikum Essen, Essen, 45122, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Medizinische Fakultat Mannheim der Universitat Heidelberg, Mannheim, 68167, Germany|Universitatsklinikum Munster, Munster, 48149, Germany|Studienpraxis Urologie, Nuertingen, 72622, Germany|Universitatsklinikum Tubingen, Tubingen, 72076, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, 97080, Germany|Semmelweis Egyetem, Budapest, 1082, Hungary|Orszagos Onkologiai Intezet, "C" Belgyogyaszati-Onkologiai es Klinikai Farmakogogiai Osztaly, Budapest, 1122, Hungary|Debreceni Egyetem, Debrecen, 4032, Hungary|Szabolcs- Szatmar-Bereg Megyei Korhazak es Egyetemi Oktato Korhaz, Nyiregyhaza, 4400, Hungary|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forli - Cesena, 47014, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Rome, 00152, Italy|Azienda Ospedaliero-Universitaria S. Luigi Gonzaga-SCDU Oncologia Medica, Orbassano, Torino/piemonte, 10043, Italy|AULSS3 Serenissima - Ospedale dell'Angelo - Oncologia Medica, Mestre, Venezia, 30174, Italy|Azienda Socio Sanitaria Territoriale di Cremona (Istituti Ospitalieri di Cremona), Cremona, 26100, Italy|SD Oncologia Clinica Sperimentale di Uro-Ginecologia, Napoli, 80131, Italy|IOV - Istituto Oncologico Veneto IRCCS - U.O. Oncologia Medica 1, Padova, 35128, Italy|Azienda Ospedaliero Universitari di Parma - U.O. Oncologia Medica, Parma, 43126, Italy|Azienda Ospedaliero Universitaria di Parma - U.O. Oncologia Medica, Parma, 43126, Italy|Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, 10126, Italy|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Radboud UMC, Nijmegen, THE Netherlands, 6525 GA, Netherlands|Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza, Brzozow, 36-200, Poland|Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Kielce, 25-734, Poland|Hospital Virgen de la Victoria, Malaga, Malga, 29010, Spain|Clinica Universidad de Navarra-Oncology Service, Pamplona, Navarra, 31008, Spain|Hospital General Vall D'Hebron-Oncology Service, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario Quironsalud Madrid-Oncology Service, Madrid, 28223, Spain|Instituto Valenciano de Oncologia (IVO-FINCIVO), Valencia, 46009, Spain|Hospital Universitari i Politecnic La Fe, Valencia, 46026, Spain|Mount Vernon Hospital, Northwood, Middlesex, HA6 2RN, United Kingdom|The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust , Sycamore House, Sutton, Surrey, SM2 5PT, United Kingdom|Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom Less << |
NCT06193525 | Advanced Breast Cancer | PHASE2 | RECRUITING | 2025-12-25 | Leiden University Medical Cent... More >>er, Leiden, Zuid-Holland, 2333ZA, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, 3015GD, Netherlands|Groningen University Medical Center, Groningen, 9713GZ, Netherlands Less << |
NCT05141708 | Metastatic Breast Cancer|Breas... More >>t Neoplasms Less << | COMPLETED | 2022-06-30 | Pfizer Inc., New York, New Yor... More >>k, 10017, United States Less << | |
NCT03042910 | Solid Tumor | PHASE1 | COMPLETED | 2017-06-22 | CBCC Global Research, Inc. at ... More >>Comprehensive Blood and Cancer Center, Bakersfield, California, 93309, United States|UCLA Hematology/Oncology - Burbank, Burbank, California, 91505, United States|St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, 92835, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D., Los Angeles, California, 90095-7349, United States|Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, 90095, United States|TRIO-US Central Administration, Los Angeles, California, 90095, United States|UCLA Hematology/Oncology, Los Angeles, California, 90095, United States|UCLA West Medical Pharmacy. Attn: Steven L. Wong, Pharm.D., Los Angeles, California, 90095, United States|UCLA Hematology/Oncology - Pasadena, Pasadena, California, 91105, United States|UCLA Hematology/Oncology - Porter Ranch, Porter Ranch, California, 91326, United States|Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach, California, 90277, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, 90404, United States|UCLA Hematology/Oncology - Santa Clarita, Valencia, California, 91355, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, 33021, United States|Memorial Regional Hospital, Hollywood, Florida, 33021, United States|Orlando Health, Inc., Orlando, Florida, 32806, United States|Memorial Hospital West, Pembroke Pines, Florida, 33028, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46804, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46845, United States Less << |
NCT02921919 | Cancer | PHASE2 | COMPLETED | 2021-07-20 | UCLA Hematology/Oncology - Alh... More >>ambra, Alhambra, California, 91801, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, 93309, United States|UCLA Hematology/Oncology - Burbank, Burbank, California, 91505, United States|St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, 92835, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D., Los Angeles, California, 90095-7349, United States|(IRB# 16-001189) Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, 90095, United States|TRIO-US Central Administration, Los Angeles, California, 90095, United States|UCLA Hematology/Oncology, Los Angeles, California, 90095, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D., Los Angeles, California, 90095, United States|UCLA Hematology/Oncology - Pasadena, Pasadena, California, 91105, United States|UCLA Hematology/Oncology - Porter Ranch, Porter Ranch, California, 91326, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, 90404, United States|UCLA Torrance Oncology, Torrance, California, 90505, United States|UCLA Hematology/Oncology - Santa Clarita, Valencia, California, 91355, United States|Orlando Health, Inc., Orlando, Florida, 32806, United States|Memorial Hospital West, Pembroke Pines, Florida, 33028, United States|IU Health Bloomington Hospital, Bloomington, Indiana, 47403, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46804, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46845, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Investigational Drug Senvices, Indianapolis, Indiana, 46202, United States|IU Health University Hospital, Indianapolis, Indiana, 46202, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|Juravinski Cancer Clinic, Hamilton, Ontario, L8L 8E7, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Institut Paoli-Calmettes, Marseille cedex 09, 13273, France|Frauenklinik des Universitaetsklinikums Erlangen, Erlangen, 91054, Germany|Magyar Honvedseg Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, 1062, Hungary|Orszagos Onkologiai Intezet "B" Belgyogyaszati-Onkologiai Osztaly es Klinikai Farmakologiai Osztaly, Budapest, H-1122, Hungary|Arensia Exploratory Medicine, Institutia Medico-Sanitara Publica Institutul Oncologic, Chisinau, MD-2025, Moldova, Republic of|Szpital Lux Med, Warszawa, 02-801, Poland|FSBEI HE " First Moscow State Medical University n.a. I.M. Sechenov" of the MoH of the RF, Moscow, 119991, Russian Federation|Medical Technologies LLC, Saint-Petersburg, 196105, Russian Federation|Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, United Kingdom Less << |
NCT03990896 | Breast Cancer | PHASE2 | RECRUITING | 2025-12-31 | UCSF Medical Center-Mission Ba... More >>y/Benioff Children's Hospital, San Francisco, California, 94143, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Northwestern University, Chicago, Illinois, 60611, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Weill Cornell Medicine, New York, New York, 10065, United States|Vanderbilt University, Nashville, Tennessee, 37232-6307, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less << |
NCT04740190 | Recurrent Glioma|Recurrent Gli... More >>oblastoma|Poly ADP Ribose Polymerase (PARP) Inhibitor|PTEN Gene Inactivation|IDH Mutation Less << | PHASE2 | UNKNOWN | 2023-12-31 | Department of Clinical Oncolog... More >>y, Hong Kong, Hong Kong Less << |
NCT05650476 | Metastatic Castration-Resistan... More >>t Prostate Cancer Less << | AVAILABLE | - | - | |
NCT05288127 | HRD 100 Gene Expression High|T... More >>riple Negative Breast Cancer Less << | PHASE2 | RECRUITING | 2025-11-25 | University Malaya Medical Cent... More >>re, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, 59100, Malaysia Less << |
NCT04462809 | Advanced Malignant Pleural or ... More >>Peritoneal Mesothelioma Less << | PHASE2 | UNKNOWN | 2024-10-01 | - |
NCT02997176 | Advanced Solid Tumors | PHASE1 | COMPLETED | 2020-02-12 | UCLA Hematology/Oncology - Alh... More >>ambra, Alhambra, California, 91801, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, 93309, United States|St. Joseph Heritage Healthcare, Fullerton, California, 92835, United States|St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, 92835, United States|UCLA Hematology/Oncology, Los Angeles, California, 90095, United States|UCLA Hematology/Oncology - Porter Ranch, Porter Ranch, California, 91326, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, 90404, United States|UCLA Torrance Oncology, Torrance, California, 90505, United States|UCLA Hematology/Oncology - Santa Clarita, Valencia, California, 91355, United States|Orlando Health, Inc., Orlando, Florida, 32806, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less << |
NCT04987931 | Breast Cancer | COMPLETED | 2021-10-11 | Pfizer Inc, New York, New York... More >>, 10017, United States Less << | |
NCT05053854 | Neuroendocrine Tumors | PHASE1 | RECRUITING | 2029-06-30 | Peter MacCallum Cancer Centre,... More >> Melbourne, Victoria, 3000, Australia Less << |
NCT02997163 | Advanced Solid Tumors | PHASE1 | COMPLETED | 2019-01-30 | Fort Wayne Medical Oncology an... More >>d Hematology, Inc., Fort Wayne, Indiana, 46804, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46845, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, 48334, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 08901, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada Less << |
NCT01286987 | Advanced or Recurrent Solid Tu... More >>mors|Breast Neoplasms|Ovarian Cancer, Epithelial|Ewing Sarcoma|Small Cell Lung Carcinoma|Prostate Cancer|Pancreas Cancer Less << | PHASE1 | COMPLETED | 2017-01-30 | Scottsdale Healthcare, Scottsd... More >>ale, Arizona, 85258, United States|Virginia G. Piper Cancer Center Research Pharmacy, Scottsdale, Arizona, 85258, United States|(IRB# 12-000131) Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, 90095, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, 90095, United States|UCLA Hematology/Oncology, Los Angeles, California, 90095, United States|Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles, California, 90095, United States|Santa Monica - UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, 90404, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, 90404, United States|IU Health Bloomington Hospital, Bloomington, Indiana, 47403, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Investigational Drug Services, Indianapolis, Indiana, 46202, United States|IU Health University Hospital, Indianapolis, Indiana, 46202, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, SM2 5PT, United Kingdom Less << |
NCT03070548 | Advanced Solid Tumors | PHASE1 | COMPLETED | 2025-06-17 | PRA Magyarorszag Kft, Fazis I-... More >>es Klinikai Farmakologiai Vizsgalohely, Budapest, 1077, Hungary Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.63mL 0.53mL 0.26mL |
13.15mL 2.63mL 1.31mL |
26.29mL 5.26mL 2.63mL |